Molecular docking studies of new thiazolidin‑4‑one derivatives as combretastatin A4 analogues
DOI:
https://doi.org/10.60988/p.v37i2S.222Keywords:
anti-cancer; combretastatin A4; tubulin; thiazolidin‑4‑one; molecular dockingAbstract
In the present study, a series of thiazolidin-4-one derivatives were designed as analogues of combretastatin A4 (CA4); a known anti-tubulin agent. The molecular structures incorporate either a 3,4,5-trisubstituted phenyl ring or a 3-alkoxy-4-methoxyphenyl ring, with the two aromatic systems connected via an amide linkage and a thiazolidin-4-one scaffold. Structural variation was introduced through different substituents (R groups) on the 4-methoxyphenyl ring. All compounds, along with CA4 as the reference molecule, were subjected to molecular docking studies targeting the tubulin β-2B chain (Protein Data Bank code: 8QEA). The docking results revealed that the newly synthesized molecules exhibit binding affinities and inhibition constant (Ki) values comparable to those of CA4. These findings suggest that the designed thiazolidin-4-one derivatives warrant further experimental investigation for their potential as anti-tubulin (i.e., anti-cancer) agents.
References
1. Anand U., Dey A., Chandel A.K.S., Sanyal R., Mishra A., Pandey D.K., et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 10(4), 1367–1401, 2022. DOI: 10.1016/j.gendis.2022.02.007
2. Khwaja S., Kumar K., Das R., Negi A.S. Microtubule associated proteins as targets for anticancer drug development. Bioorg. Chem. 116, 105320, 2021. DOI: 10.1016/j.bioorg.2021.105320
3. Naumova N., Šachl R. Regulation of cell death by mitochondrial transport systems of calcium and Bcl-2 proteins. Membranes (Basel) 10(10), 299, 2020. DOI: 10.3390/membranes10100299
4. Thomas E., Gopalakrishnan V., Hegde M., Kumar S., Karki S.S., Raghavan S.C., et al. A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells. Sci. Rep. 6, 34653, 2016. DOI: 10.1038/srep34653
5. Gaspari R., Prota A.E., Bargsten K., Cavalli A., Steinmetz M.O. Structural basis of cis- and trans-combretastatin binding to tubulin. Chem 2(1), 102–113, 2017. DOI: 10.1016/j.chempr.2016.12.005
6. Singh S.B. Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review. Nat. Prod. Rep. 41(2), 298–322, 2024. DOI: 10.1039/d3np00053b
7. Abdul Hussein S.A., Razzak Mahmood A.A., Tahtamouni L.H., Balakit A.A., Yaseen Y.S., Al-Hasani R.A. New combretastatin analogs as anticancer agents: design, synthesis, microtubules polymerization inhibition, and molecular docking studies. Chem. Biodivers. 20(4), e202201206, 2023. DOI: 10.1002/cbdv.202201206
8. Neese F. Software update: the ORCA program system – version 5.0. WIREs Comput. Mol. Sci. 12(5), e1606, 2022. DOI: 10.1002/wcms.1606
9. Becke A.D. A new mixing of Hartree–Fock and local density-functional theories. J. Chem. Phys. 98(2), 1372–1377, 1993. DOI: 10.1063/1.464304
10. Weigend F., Ahlrichs R. Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy. Phys. Chem. Chem. Phys. 7(18), 3297–3305, 2005. DOI: 10.1039/b508541a
